JPMorgan raised the firm’s price target on SpringWorks Therapeutics to $74 from $68 and keeps an Overweight rating on the shares. The analyst also added the shares to the firm’s Analyst Focus List. Ogsiveo patient adds in desmoid tumors will come from incidence, actively treated, as well as, “wait and watch” populations in the near-term, the analyst tells investors in a research note. The firm says physician feedback suggests Ogsiveo is a “treatment paradigm changing product.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SWTX:
- SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
- SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Goldman Sachs pharmaceuticals analysts hold an analyst/industry conference call
- SpringWorks Therapeutics 9.483M share Spot Secondary priced at $29.00
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue